Faculty profile
Charity Evans
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis: A Multiregional Population-Based Study.
Neurology · 2024
Psychiatric Comorbidity During the Prodromal Period in Patients With Multiple Sclerosis.
Neurology · 2023
Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival.
Neurology(R) neuroimmunology & neuroinflammation · 2022
Latest funding
- $1,395,381
Disease-modifying Drug Safety and Effectiveness in Multiple Sclerosis [DRUMS]
CIHR · 2017 · Co-investigator
- $1,220,175
Prescription Drug Safety and Effectiveness in Multiple Sclerosis [DRUMS]: a population-based, multi-province platform for comprehensive pharmacovigilance
CIHR · 2017 · Principal investigator
- $99,785
The BeAMS-50plus Study Benefits and Adverse Effects of Beta-interferon for Multiple Sclerosis patients aged 50 plus
CIHR · 2011 · Co-investigator
11 publications.
Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis: A Multiregional Population-Based Study.
Ng HS, Zhu F, Zhao Y, Yao S, Lu X, Ekuma O, Evans C, Fisk JD, Marrie RA, Tremlett H
Psychiatric Comorbidity During the Prodromal Period in Patients With Multiple Sclerosis.
Chertcoff AS, Yusuf FLA, Zhu F, Evans C, Fisk JD, Zhao Y, Marrie RA, Tremlett H
Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival.
Ng HS, Zhu F, Kingwell E, Yao S, Ekuma O, Evans C, Fisk JD, Marrie RA, Zhao Y, Tremlett H
Validation of an algorithm for identifying MS cases in administrative health claims datasets.
Culpepper WJ, Marrie RA, Langer-Gould A, Wallin MT, Campbell JD, Nelson LM, Kaye WE, Wagner L, Tremlett H, Chen LH, Leung S, Evans C, Yao S, LaRocca NG, United States Multiple Sclerosis Prevalence Workgroup (MSPWG)
Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.
Kowalec K, McKay KA, Patten SB, Fisk JD, Evans C, Tremlett H, Marrie RA, CIHR Team in Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS)
Evaluating the safety of β-interferons in MS: A series of nested case-control studies.
de Jong HJI, Kingwell E, Shirani A, Cohen Tervaert JW, Hupperts R, Zhao Y, Zhu F, Evans C, van der Kop ML, Traboulsee A, Gustafson P, Petkau J, Marrie RA, Tremlett H, British Columbia Multiple Sclerosis Clinic Neurologists
Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records.
McKay KA, Evans C, Fisk JD, Patten SB, Fiest K, Marrie RA, Tremlett H
Incidence and prevalence of multiple sclerosis in the Americas: a systematic review.
Evans C, Beland SG, Kulaga S, Wolfson C, Kingwell E, Marriott J, Koch M, Makhani N, Morrow S, Fisk J, Dykeman J, Jetté N, Pringsheim T, Marrie RA
Hospital admissions and MS: temporal trends and patient characteristics.
Evans C, Kingwell E, Zhu F, Oger J, Zhao Y, Tremlett H
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H
Disease-modifying Drug Safety and Effectiveness in Multiple Sclerosis [DRUMS]
Principal investigators: Tremlett, Helen L
Keywords: Disability; Disease Prevention; Drug Effectiveness; Drug Repurposing; Health Administrative Data; Mortality; Multiple Sclerosis; Pharmacoepidemiology; Pharmacovigilance; Population-Based Cohorts
Prescription Drug Safety and Effectiveness in Multiple Sclerosis [DRUMS]: a population-based, multi-province platform for comprehensive pharmacovigilance
Principal investigators: Tremlett, Helen L; Evans, Charity D; Fisk, John D; Marrie, Ruth Ann; Patten, Scott B
Keywords: Chronic Disease; Disability; Disease Modifying Drugs; Drug Effectiveness; Drug Safety; Health Administrative Data; Multiple Sclerosis; Pharmacovigilance; Population-Based; Post-Marketing, Real World
The BeAMS-50plus Study Benefits and Adverse Effects of Beta-interferon for Multiple Sclerosis patients aged 50 plus
Principal investigators: Tremlett, Helen L
Keywords: Ageing; Data Linkage; Drug Adverse Effects; Drug Effectiveness; Epidemiology; Health Care Utilization; Middle Age; Multiple Sclerosis; Underrepresented Populations
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Medicine/Neurology
- College of Pharmacy
- Other
Co-authors at University of British Columbia, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Helen Tremlett
Medicine/Neurology
10 shared papers, latest 2024
Charity Evans
Faculty
6 shared papers, latest 2024
John Fisk
Medicine/Neurology
1 shared papers, latest 2013
Anthony Traboulsee
Medicine/Neurology
1 shared papers, latest 2017
Kaarina Kowalec
Faculty
1 shared papers, latest 2017
Kaarina Kowalec
College of Pharmacy
1 shared papers, latest 2017
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.